AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 41 |
Market Cap | 2.08B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.08 |
PE Ratio (ttm) | -20.83 |
Forward PE | n/a |
Analyst | Buy |
Ask | 46.92 |
Volume | 773,537 |
Avg. Volume (20D) | 376,100 |
Open | 44.87 |
Previous Close | 44.00 |
Day's Range | 43.20 - 45.10 |
52-Week Range | 23.14 - 48.89 |
Beta | undefined |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...
Analyst Forecast
According to 10 analyst ratings, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is $63, which is an increase of 45.40% from the latest price.
Next Earnings Release
Analysts project revenue of $86.85M, reflecting a 24.87% YoY growth and earnings per share of -0.34, making a -48.48% decrease YoY.
2 months ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call TranscriptMirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief E...
2 months ago · businesswire.com
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.
2 months ago · businesswire.com
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingFOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .